Adcetris 50mg Injection contains Brentuximab Vedotin, an antibody-drug conjugate. Hodgkin's lymphoma and systemic anaplastic large cell lymphoma are the two main cancer forms that it is used to treat. The protein CD30, which is expressed on the surface of some cancer cells, is the target of the active ingredient.

Brand Name: Adcetris

Composition: Brentuximab Vedotin

Mechanism of Action:

The drug Brentuximab Vedotin is a targeted treatment that combines monomethyl auristatin E, a cytotoxic chemical, with a monoclonal antibody that is particularly made to attach to CD30, a protein found on the surface of some cancer cells. The cytotoxic drug can be precisely delivered to the cancer cells thanks to this combination. The cancer cells are destroyed when the cytotoxic chemical enters the cells and damages the microtubules, which are vital components for cell division.

Uses:

Hodgkin's lymphoma

Dosage and Administration:

Given by intravenous infusion, usually over a period of 30 minutes, in accordance with the oncologist's recommended dosage and timetable.

Side Effects:

• Peripheral neuropathy
• Nausea
• Vomiting
• Fever
• Dizziness
• Fatigue
• Anemia
• Neutropenia

Safety Advise:

Liver  

Patients with hepatic impairment may require dose modifications. Throughout treatment, liver function should be routinely assessed. Kindly speak with your healthcare provider.

Kidney  

Patients with renal impairment may require dose modifications. Throughout treatment, kidney function should be routinely assessed. Kindly speak with your healthcare provider.

Pregnancy  

As Adcetris may harm the fetus, it is not advised to use it during pregnancy. Kindly speak with your healthcare provider.

Breast Feeding  

Adcetris 50mg Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby. Kindly speak with your healthcare provider.

Alcohol    

Drinking alcohol while taking Adcetris 50mg Injection is not advised. Kindly speak with your healthcare provider.

Storage:

Store the vial at 2°C to 8°C (36°F to 46°F) in a refrigerator. Do not freeze. Protect from light.

How to use this Medication?

In a hospital or doctor's office, a doctor or nurse will mix a powdered form of benuximab vedotin with fluid and administer it intravenously (into a vein) during a 30-minute period. Depending on the condition for which you are receiving therapy, benuximab vedotin is typically injected once every two to three weeks for as long as your doctor advises.

If you have certain side effects, your doctor might need to stop your therapy, change your dosage, or postpone it. Throughout your brentuximab vedotin injectable treatment, be sure to let your doctor know how you're feeling.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Takeda Pharmaceuticals India Pvt. Ltd

Address: The Capital A 1504, 16 Floor, G Block, Bandra Kurla Complex-Bandra East, Mumbai - 400051

Country of origin: India